10.6084/m9.figshare.5123497.v1 Gaitanis G. Gaitanis G. Spyridonos P. Spyridonos P. Patmanidis K. Patmanidis K. Koulouras V. Koulouras V. Nakos G. Nakos G. Tzaphlidou M. Tzaphlidou M. Bassukas I.D. Bassukas I.D. Supplementary Material for: Treatment of Toxic Epidermal Necrolysis with the Combination of Infliximab and High-Dose Intravenous Immunoglobulin Karger Publishers 2012 Toxic epidermal necrolysis Infliximab Immunoglobulin Adverse drug reaction 2012-05-03 00:00:00 Dataset https://karger.figshare.com/articles/dataset/Supplementary_Material_for_Treatment_of_Toxic_Epidermal_Necrolysis_with_the_Combination_of_Infliximab_and_High-Dose_Intravenous_Immunoglobulin/5123497 <b><i>Background:</i></b> Therapeutic evidence for toxic epidermal necrolysis (TEN) is indicative for high-dose intravenous immunoglobulin yet inconclusive for corticosteroids. <b><i>Objective:</i></b> To describe the combination of corticosteroids, infliximab and a high-dose intravenous immunoglobulin course for TEN. <b><i>Patients and Methods:</i></b> In three patients (SCORTEN survival probabilities: 41.7%, 64.2%, 41.7%) disease control was evaluated by (a) employing quantitative image analysis to measure progression of skin detachment and (b) patients’ outcome (complete re-epithelization). Published cases of TEN treatments with infliximab were retrieved from PubMed. <b><i>Results:</i></b> Within 48 h skin disease progression was arrested in all patients. Two patients were discharged after 3 weeks without any sequels from skin or conjunctivae. One patient passed away on the ninth day, however with noticeably improved skin (mortality rate: 33% observed vs. 50% expected). A PubMed search retrieved five TEN patients treated successfully with infliximab. <b><i>Conclusion:</i></b> The described combination presents a feasible therapeutic alternative for TEN that warrants further evaluation.